Bronco Magnimox

Quick links

Choose a section

Quick links to important sections

Advertisements

Bronco Magnimox

Advertisements
Advertisements

Method of action: Expectorant

Treatment option:

Advertisements

Overview of Bronco Magnimox

Property Description
Active Ingredients Amoxicillin, Bromhexine
Form Tablets, Capsules, Oral Suspension
Pharmacological Class Combination Antibacterial and Mucolytic Agent
Common Use Managing infections with excessive mucus
Origin Semisynthetic (Amoxicillin) / Synthetic Derivative (Bromhexine)

What Type of Medicine is Bronco Magnimox?

Bronco Magnimox is defined as a Fixed-Dose Combination (FDC) preparation designed for systemic administration via the oral route, simultaneously categorized as an antibacterial agent and a mucolytic agent. The FDC status provides a distinctive feature, integrating two active therapeutic substances into a single entity to streamline treatment. This combination is based on the pharmacological principle that mucolytics can enhance the bioavailability of antibiotics in respiratory tissues. It is widely available in solid dosage forms, such as tablets or capsules, and also exists as an oral suspension.


Composition and Pharmacological Class

The active components are the INN substances Amoxicillin and Bromhexine. Amoxicillin is classified as a beta-Lactam antibiotic, known specifically as a semisynthetic penicillin. The second substance, Bromhexine, functions as an effective mucolytic agent and broncho-secretolytic. The formulation leverages the specific benefit of the mucolytic to break down thick sputum while the antibiotic targets susceptible pathogens.


General Purpose of the Combined Formulation

The general therapeutic purpose of this combined formulation is to provide coordinated management for respiratory tract infections (RTI) when complicated by the production of thick, excessive mucus. The formulation delivers a unique, synergistic benefit: Amoxicillin focuses on eliminating susceptible bacterial pathogens, while Bromhexine acts by facilitating the depolymerization of mucopolysaccharides to reduce sputum viscosity. This coordinated effort supports the effective clearance of secretions from the airways, thereby easing the physical symptoms associated with tenacious phlegm in the respiratory system.

Advertisements

What side effects are possible with Bronco Magnimox?

Possible Side Effects and Safety Information

The safety profile of this fixed-dose combination, comprising Amoxicillin and Bromhexine, is primarily defined by the officially documented adverse reactions associated with its antibacterial component. The regulatory framework classifies possible effects by frequency and the organ system affected, providing a structured understanding of the medicine’s risk landscape.


Documented Adverse Reactions and Frequencies

Adverse reactions most frequently reported in regulatory documentation are categorized as Common (affecting more than 1 in 100 people) and primarily involve the Gastrointestinal system (e.g., diarrhea, nausea, vomiting) and Skin (e.g., rash). Uncommon effects may include upper abdominal pain and specific dermatological reactions like urticaria.

System-Organ Class Examples of Documented Effects
Gastrointestinal Disorders Diarrhea, nausea, vomiting, abdominal pain
Skin and Subcutaneous Tissue Rash, urticaria, pruritus
Immune System Disorders Anaphylactic reaction, angioedema
Nervous System Disorders Headache, dizziness, confusion, convulsions

Serious Adverse Reactions and Restrictions

Official labeling emphasizes the potential for Serious Adverse Reactions (SARs) typical of beta-lactam antibiotics. These include severe, though low-frequency, events such as life-threatening anaphylactic reactions and severe cutaneous adverse reactions like Stevens-Johnson syndrome (SJS). A serious risk associated with nearly all antibacterials is Clostridioides difficile-Associated Diarrhea (CDAD), which may occur during or up to two months after administration.

Use is contraindicated in patients with a history of a serious hypersensitivity reaction to Amoxicillin or other beta-lactam drugs. Furthermore, specific population-based safety notes advise against use in patients with infectious mononucleosis and counsel caution in individuals presenting with severe hepatic or renal impairment.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Bronco Magnimox overdose is primarily defined by severe systemic manifestations linked to its active components. Overexposure may present with pronounced gastrointestinal symptoms such as nausea, vomiting, and diarrhea. More critical documented effects involve the renal and central nervous systems. Amoxicillin overdose is associated with the occurrence of Crystalluria, which has been documented in regulatory sources as potentially leading to Acute renal failure in severe cases. Central Nervous System effects, including Excitement, Agitation, and Convulsions, may also manifest, with a stated higher risk for these neurological events in patients with impaired renal function.

In the event of a suspected overdose, the regulatory mandate is to seek immediate medical attention or contact emergency services without delay. This urgency is driven by the potential for life-threatening outcomes like acute renal injury or severe seizures. Management is defined by supportive measures: Symptomatic and supportive treatment is the principal approach, as no specific antidote is known. Procedures such as maintaining adequate fluid intake are listed in official documents to promote diuresis and reduce the risk of crystalluria. Hospital monitoring of renal and neurological function may be required.

Advertisements

Therapeutic Uses of Bronco Magnimox

The primary therapeutic purpose of Bronco Magnimox is generally used to provide coordinated management for acute conditions in the respiratory system when they are complicated by excessive, thick mucus. This formulation is commonly used to address two key problems simultaneously, offering supportive benefits for patients experiencing acute symptomatic distress. In this therapeutic context, the antibacterial component is considered relevant for treating infections like pneumonia and bronchitis, which form the core conditions targeted by this combination.

The medication is commonly applied in clinical settings for the treatment of acute bacterial respiratory tract infections (RTIs), including conditions such as bacterial bronchitis, sinusitis, and tonsillitis. Its use is considered relevant where susceptible bacterial pathogens are implicated as the cause of the illness. The core benefit to the patient is to support the body's natural processes in managing the acute phase by addressing the bacterial component of the illness, and contributes to easing the overall symptom load during that period.

The practical benefit is relevant for symptoms associated with highly viscous mucus, which may assist with easier expectoration and supports functional stability related to airway clearance, thereby helping ease the patient's physical discomfort and symptom burden during the acute phase.


Therapeutic Focus: Management of Productive Cough

The medication may assist with managing the symptom burden associated with a cough that produces symptoms related to highly viscous mucus by assisting with symptoms that interfere with daily functioning.


Regulatory References

  1. NIH MedlinePlus overview of Amoxicillin
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Bronco Magnimox?

This eligibility profile is based strictly on regulatory requirements for fixed-dose combinations containing Amoxicillin and Bromhexine.

Classification Population or Condition
Absolute Contraindication History of severe hypersensitivity or allergic reaction to Penicillins (like Amoxicillin), other Beta-Lactams, or Bromhexine itself.
Individuals with Infectious Mononucleosis (due to increased risk of rash).
Patients with a history of jaundice or hepatic dysfunction associated with previous Amoxicillin use.
Conditional/Restricted Use Severe Renal Impairment (GFR < 30 mL/min) requires a reduction in the maximum allowable dose of the Amoxicillin component.
Severe Hepatic Impairment and history of gastric ulceration require caution and medical monitoring.
Age-Related Ineligibility Children under 6 years of age are generally ineligible for solid dosage forms (tablets/capsules); liquid formulations may be required.
Developmental Status Breastfeeding mothers are not recommended to use the medicine as both components may be excreted into breast milk. Use during pregnancy is generally restricted to when the benefit clearly outweighs the risk.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details officially documented interactions for Bronco Magnimox, a combination of Amoxicillin and Bromhexine, as outlined in government regulatory information.

Documented Pharmacological Interactions

Interacting Substance Official Interaction Pattern
Probenecid Reduces the renal tubular secretion of Amoxicillin, resulting in increased and prolonged plasma concentrations of the antibiotic component.
Oral Anticoagulants (e.g., Warfarin) May increase the prolongation of prothrombin time (INR), increasing the official risk of bleeding.
Allopurinol Associated with an increased incidence of rash when co-administered with Amoxicillin.
Cough Suppressants (Antitussives) Contraindicated combination, as inhibiting the cough reflex may lead to the accumulation of secretions diluted by the Bromhexine component.
Oral Contraceptives The Amoxicillin component may potentially reduce the efficacy of combined estrogen/progesterone oral contraceptives.

Formulation and Procedural Notes

The formulation relies on an inherent interaction where the Bromhexine component increases the local concentration and penetration of Amoxicillin into respiratory secretions. Furthermore, the Amoxicillin component may cause false-positive results for glucose when specific copper reduction tests (e.g., Clinitest) are used for urine analysis, necessitating the use of enzymatic glucose oxidase tests.

Advertisements

Mechanism of Action

Targeted Inhibition of Bacterial Cell Wall Production

This mechanistic domain centers on the Amoxicillin component, which functions as an irreversible inhibitor of bacterial Penicillin-Binding Proteins (PBPs). PBPs are the key transpeptidase enzymes required for the final structural cross-linking of the peptidoglycan cell wall. By binding covalently to PBPs, the molecule causes defects in cell wall integrity, which ultimately leads to osmotic lysis and the resulting bactericidal effect against susceptible pathogens.


Alteration of Mucus Rheology and Secretion Transport

The Bromhexine component engages in the direct depolymerization of the highly structured acidic mucopolysaccharide fibers that contribute to high viscoelasticity. Through chemical cleavage of internal bonds and stimulation of lysosomal enzymes, this action significantly reduces secretion viscosity. This change in physical properties enhances the efficiency of the mucociliary clearance mechanism, facilitating the physical mobilization of secretions from the airways.


Functional Coordination of Dual Mechanisms

Bronco Magnimox operates via a strategy of functional complementarity: the mucolytic action physically modifies the bronchial environment, creating a less viscous medium that can facilitate the diffusion and localized concentration of the Amoxicillin component within infected respiratory tissues. This coordination addresses both the consequence of disrupting bacterial survival mechanisms and the concurrent mechanical impedance caused by highly viscous secretions.

Advertisements

Dosage and Administration Information

How to Use Bronco Magnimox

Bronco Magnimox is a Fixed-Dose Combination (FDC) preparation intended solely for oral administration, available in solid dosage forms such as tablets and capsules, or as a powder for oral suspension. The usage pattern is based on the administration protocol for its antibacterial component.


Standard Administration Protocol

The medicine is administered in a divided dose schedule, typically taken two (BID) or three (TID) times daily (e.g., every 12 hours or every 8 hours), to maintain consistent drug exposure. Absorption is generally not significantly affected by meals, allowing the medicine to be taken with or without food. If the oral suspension form is used, the powder must be reconstituted with the specified volume of water and shaken vigorously before the initial dose.

Course Duration and Dose Adjustments

Bronco Magnimox is intended for short-term use, with the course duration typically limited to 7 to 14 days for acute conditions. For adult patients with severe renal impairment (reduced kidney function), the administration requires a dose reduction or extension of the dosing interval to prevent accumulation of the antibiotic component. If a dose is missed, the general protocol is to take it as soon as possible, but if it is near the time for the next scheduled dose, the missed dose must be skipped, and a double dose should never be taken.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bronco Magnimox

This section provides an overview of the research record concerning the fixed-dose combination of Amoxicillin and Bromhexine, focusing on the types of clinical studies that have been conducted and the known limits of the current evidence. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes.


Evidence for use in Acute Bacterial Respiratory Tract Infections (RTIs)

The clinical evaluation was studied for the combination of amoxicillin and bromhexine in the context of acute lower respiratory tract infections (LRTI). These investigations consisted mainly of Randomized Controlled Trials (RCTs), where the combination therapy was observed in trials comparing it against the antibiotic component (Amoxicillin) alone. Research examined outcomes related to physical discomfort and outcomes reflecting daily functioning. Findings were mixed across different research efforts. Scientific reviews indicate that the overall certainty remains low to moderate because many older trials had limitations in their design. Comparative evidence is lacking to provide a clearer picture against monotherapy alone.


Research on Mucus Clearance and Bronchiectasis

The combination was studied for conditions characterized by fluctuating or episodic manifestations involving excessive mucus, such as acute exacerbations of bronchiectasis. Research examined outcomes related to sputum properties, including production volume and difficulty in expectoration, alongside some monitoring of lung function measurements. The findings contribute to the broader evidence landscape by providing insight into how the product was associated with patterns of the clearance of respiratory secretions during the acute phase. However, the evidence is limited for this specific use.


What is Still Uncertain About Bronco Magnimox

Research contributes to the broader evidence landscape, but it also highlights what is known—and what is still uncertain. The main limitations noted in the research record are consistent across indications: Evidence quality varies across studies, sample sizes were modest in many trials, and long-term effects are not fully established. Comparative evidence is lacking in some areas, making it difficult to fully contextualize the value of the fixed-dose combination versus the antibiotic administered alone.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Bronco Magnimox (FAQ)


Q: Is it normal to feel tired or drowsy after starting Bronco Magnimox?

Official safety documentation indicates that dizziness and drowsiness have been reported as potential adverse reactions. Because of this possibility, regulatory counseling advises individuals to use caution. It is generally advised to avoid activities requiring high mental alertness, such as driving or operating machinery, until an individual knows how the medicine affects them.

Q: Is Bronco Magnimox safe for older adults (seniors)?

Official guidelines note that use in older adults should be carefully monitored. This is primarily because reduced kidney function is more common in this population. If kidney function is decreased, official guidelines indicate the potential need for a change in administration protocol.

Q: Can women who are planning pregnancy use Bronco Magnimox?

According to regulatory data for the active components, there is no evidence to suggest that this medicine affects fertility in men or women. However, for women who are planning to become pregnant, official guidance emphasizes discussing all current medications with a healthcare professional before starting treatment.

Q: What is the general long-term expectation when taking Bronco Magnimox?

Official documentation specifies that Bronco Magnimox is intended only for short courses of treatment, generally lasting 7 to 14 days. The research record reflects this short-term use, and consequently, the safety and effects associated with using this medication long-term are not fully established in regulatory data.

Q: What age group is Bronco Magnimox usually prescribed to?

Bronco Magnimox is prescribed to a wide range of patients, including both adults and children. The eligibility section of the official documents states that solid dosage forms, such as tablets or capsules, are generally not approved for use in children under 6 years old. Liquid formulations are available for younger patients.

Q: Why is it necessary to follow the prescribed timing for Bronco Magnimox doses?

The strict timing of doses is necessary to maintain a consistent concentration of the antibacterial component in the body. This consistent drug exposure is essential to fully eliminate the susceptible bacterial infection. Following this protocol is associated with supporting therapeutic effectiveness and minimizing the possibility of resistance.

Q: How does Bronco Magnimox differ in use for adults versus children?

The primary difference in use relates to the available formulation, as children often require liquid suspension, especially if they are under 6 years old. Dosage calculations for children are typically based on weight, while dose adjustments for adults are frequently dictated by the presence of reduced kidney function.

Q: What should I tell my doctor about before starting Bronco Magnimox?

Official guidelines emphasize that disclosure of a patient's full medical history is important before starting this medicine. This includes any history of allergies, especially to penicillin or related beta-lactam drugs. It is also important to mention any reduced kidney or liver function, a history of infectious mononucleosis, or the current use of oral contraceptives or blood thinning medicines.

Q: How quickly does Bronco Magnimox usually start to work?

Official patient information indicates that a patient typically begins to notice an improvement in their symptoms within the first few days of starting the prescribed course. If symptoms do not appear to improve within the expected initial time frame, consultation with a healthcare professional may be warranted.

Q: How long does the effect of Bronco Magnimox last after taking it?

The duration of the medicine's effect is accounted for by the prescribed dosing schedule, which typically involves taking the medicine every 8 or 12 hours. This divided dose schedule is designed to ensure consistent therapeutic levels are maintained in the body throughout the entire 24-hour period.

Q: Does Bronco Magnimox cause weight changes?

Weight change is not listed as one of the common or frequently reported adverse reactions described in the official regulatory documentation for Bronco Magnimox. Concerns regarding any changes noticed while using the medicine should be discussed with a healthcare provider.

Q: Can I take simple pain relievers like Tylenol (acetaminophen) with Bronco Magnimox?

The officially documented list of pharmacological interactions does not currently include the common pain reliever Acetaminophen (Tylenol). However, official counseling suggests informing a healthcare professional about all over-the-counter products planned for use before combining them with this medicine.

Q: Does Bronco Magnimox interact with supplements like vitamins or herbal products?

Regulatory patient counseling advises against starting any new over-the-counter medicines, supplements, or herbal remedies without first speaking with a healthcare professional. This guidance is in place because professional guidance is important in ensuring proper co-administration.

Q: Can people with high blood pressure use Bronco Magnimox?

Official regulatory documentation does not list high blood pressure or other cardiovascular conditions as a specific contraindication or official warning for using this medicine. However, disclosure of all existing medical conditions to a healthcare professional prior to starting treatment is generally recommended.

Q: What should I do if a potential side effect feels severe?

Official warnings emphasize that signs of a severe adverse reaction require immediate emergency medical attention. These severe reactions can include sudden difficulty breathing, swelling of the face or throat (angioedema), or signs of a serious cutaneous reaction, such as Stevens-Johnson syndrome.

Q: Is it okay to drink coffee while taking Bronco Magnimox?

Official regulatory information listing documented drug interactions does not specify coffee or caffeine products. The interaction list is focused on specific pharmacological agents and known drug-food/drink interactions that significantly alter the drug's effect.

Q: If I feel better, is it necessary to complete the full course of Bronco Magnimox?

Regulatory guidelines explicitly instruct patients to complete the full course of the medicine as prescribed by a healthcare professional, even if symptoms improve early. Stopping the medicine too soon may compromise the full eradication of the infection, and may contribute to the development of antibiotic-resistant bacteria.

Q: Does Bronco Magnimox have a black box warning in the US?

According to the official regulatory status in the United States, Bronco Magnimox does not carry a Boxed Warning. This specific warning, often informally referred to as a Black Box Warning, is reserved for drugs with certain serious, life-threatening risks.

Q: What happens if I take Bronco Magnimox for longer than prescribed?

Taking this medicine for longer than the prescribed duration is not recommended and is associated with an increased potential for serious adverse effects, such as renal problems. Regulatory documents indicate that extended use or overdosage can lead to issues like the formation of crystals in the urine (crystalluria).

Q: Does Bronco Magnimox affect my ability to drive or operate machinery?

Official patient counseling advises caution regarding activities that require attention, such as driving or operating heavy machinery. This is due to the potential for the medicine to cause side effects like dizziness or drowsiness in certain individuals. Understanding how the medicine affects an individual is important before engaging in these activities.

Q: Can I get Bronco Magnimox over the counter?

As a medicine containing an antibacterial agent, Bronco Magnimox is classified as a prescription-only medicine. It is not available for purchase over the counter and can only be obtained with a valid prescription from a licensed healthcare professional.

Q: How long do side effects from Bronco Magnimox typically last?

Official safety information indicates that the most commonly reported side effects, like nausea or mild diarrhea, are typically temporary. They often resolve on their own as the body adjusts to the medicine, or they generally stop completely shortly after the entire course of the medicine has been completed.

Advertisements

How should Bronco Magnimox be stored and disposed of?

How to Store and Dispose of Bronco Magnimox?

The official storage conditions for Bronco Magnimox are designed to ensure the stability and potency of its components. The unmixed product (tablets, capsules, or dry powder) must be stored at controlled room temperature, specifically not exceeding 30 C, and must be protected from direct sunlight.


Storage by Formulation

Formulation Required Storage Condition
Unmixed Solids/Powder Store at or below 30 C, protected from light.
Reconstituted Suspension Must be stored in a refrigerator and discarded after 10 days.

All forms of the medicine must be kept tightly closed in the original container and out of the sight and reach of children. Unused or expired Bronco Magnimox must be thrown away and not disposed of in wastewater or household trash. Disposal must adhere to local regulatory requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bronco Magnimox found in:

A-Z Index: